Literature DB >> 24029421

Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study.

Jicheng Lv1, Yihe Yang, Hong Zhang, Wenfang Chen, Xiaoxia Pan, Zhiling Guo, Caili Wang, Shen Li, Jianrong Zhang, Jianchun Zhang, Lijun Liu, Sufang Shi, Suxia Wang, Min Chen, Zhao Cui, Nan Chen, Xueqing Yu, Minghui Zhao, Haiyan Wang.   

Abstract

Crescentic IgA nephropathy (IgAN), defined as >50% crescentic glomeruli on kidney biopsy, is one of the most common causes of rapidly progressive GN. However, few studies have characterized this condition. To identify risk factors and develop a prediction model, we assessed data from patients ≥ 14 years old with crescentic IgAN who were followed ≥ 12 months. The discovery cohort comprised 52 patients from one kidney center, and the validation cohort comprised 61 patients from multiple centers. At biopsy, the mean serum creatinine (SCr) level ± SD was 4.3 ± 3.4 mg/dl, and the mean percentage of crescents was 66.4%± 15.8%. The kidney survival rates at years 1, 3, and 5 after biopsy were 57.4%± 4.7%, 45.8%± 5.1%, and 30.4%± 6.6%, respectively. Multivariate Cox regression revealed initial SCr as the only independent risk factor for ESRD (hazard ratio [HR], 1.32; 95% confidence interval [CI], 1.10 to 1.57; P=0.002). Notably, the percentage of crescents did not associate independently with ESRD. Logistic regression showed that the risk of ESRD at 1 year after biopsy increased rapidly at SCr>2.7 mg/dl and reached 90% at SCr>6.8 mg/dl (specificity=98.5%, sensitivity=64.6% for combined cohorts). In both cohorts, patients with SCr>6.8 mg/dl were less likely to recover from dialysis. Analyses in additional cohorts revealed a similar association between initial SCr and ESRD in patients with antiglomerular basement membrane disease but not ANCA-associated systemic vasculitis. In conclusion, crescentic IgAN has a poor prognosis, and initial SCr concentration may predict kidney failure in patients with this disease.

Entities:  

Mesh:

Year:  2013        PMID: 24029421      PMCID: PMC3839544          DOI: 10.1681/ASN.2012101017

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  13 in total

Review 1.  IgA nephropathy.

Authors:  Jonathan Barratt; John Feehally
Journal:  J Am Soc Nephrol       Date:  2005-06-01       Impact factor: 10.121

2.  Plasma exchange in progressive primary IgA nephropathy.

Authors:  R Coppo; B Basolo; D Roccatello; O Giachino; D Lajolo; G Martina; C Rollino; A Amore; M Costa; G Piccoli
Journal:  Int J Artif Organs       Date:  1985-07       Impact factor: 1.595

3.  Idiopathic IgA nephropathy with diffuse crescent formation.

Authors:  Zheng Tang; Yan Wu; Qing-wen Wang; Yu-sheng Yu; Wei-xing Hu; Xiao-dan Yao; Hui-ping Chen; Zhi-hong Liu; Lei-shi Li
Journal:  Am J Nephrol       Date:  2002 Sep-Dec       Impact factor: 3.754

4.  Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors.

Authors:  J P Johnson; J Moore; H A Austin; J E Balow; T T Antonovych; C B Wilson
Journal:  Medicine (Baltimore)       Date:  1985-07       Impact factor: 1.889

5.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

6.  Vasculitic IgA nephropathy: prognosis and outcome.

Authors:  Tanya Pankhurst; Julia Lepenies; Peter Nightingale; Alexander J Howie; Dwomoa Adu; Lorraine Harper
Journal:  Nephron Clin Pract       Date:  2009-04-03

Review 7.  Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome.

Authors:  Giuseppe D'Amico
Journal:  Semin Nephrol       Date:  2004-05       Impact factor: 5.299

8.  Participation of extracapillary lesions (ECL) in progression of IgA nephropathy.

Authors:  T Abe; H Kida; M Yoshimura; H Yokoyama; Y Koshino; N Tomosugi; N Hattori
Journal:  Clin Nephrol       Date:  1986-01       Impact factor: 0.975

9.  Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series.

Authors:  Christos Bantis; Maria Stangou; Christoph Schlaugat; Efstathios Alexopoulos; Aphroditi Pantzaki; Dimitrios Memmos; Katrin Ivens; Peter J Heering
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

10.  Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide.

Authors:  James A Tumlin; Verachai Lohavichan; Randy Hennigar
Journal:  Nephrol Dial Transplant       Date:  2003-07       Impact factor: 5.992

View more
  38 in total

1.  Combination of pulse cyclophosphamide and steroids in crescentic IgA nephropathy.

Authors:  R Ramachandran; P Doddi; B Nandakrishna; R Nada; V Kumar; M Rathi; H S Kohli; V Jha; V Sakhuja; K L Gupta
Journal:  Int Urol Nephrol       Date:  2015-09-28       Impact factor: 2.370

Review 2.  IgA Nephropathy.

Authors:  Jennifer C Rodrigues; Mark Haas; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

3.  The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: crescents and timing of renal biopsy.

Authors:  Rosanna Coppo; Jean-Claude Davin
Journal:  Pediatr Nephrol       Date:  2014-10-16       Impact factor: 3.714

4.  Crescentic IgA nephropathy after administration of human monoclonal interleukin-12/23p40 antibody in a patient with Crohn's disease: a case report.

Authors:  Nobuhiro Kanazawa; Yukihiro Wada; Minako Akiyama; Yasuto Shikida; Motonori Sugiyama; Maki Abe; Masayuki Iyoda; Kazuho Honda; Takanori Shibata
Journal:  CEN Case Rep       Date:  2020-02-25

Review 5.  Inflammation in IgA nephropathy.

Authors:  Thomas Rauen; Jürgen Floege
Journal:  Pediatr Nephrol       Date:  2017-03-14       Impact factor: 3.714

6.  Crescentic IgA nephropathy in children.

Authors:  Yuko Shima; Koichi Nakanishi; Taketsugu Hama; Hironobu Mukaiyama; Masashi Sato; Yu Tanaka; Ryojiro Tanaka; Hiroshi Kaito; Kandai Nozu; Mayumi Sako; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2020-01-28       Impact factor: 3.714

7.  Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

Authors:  Thomas Rauen; Christina Fitzner; Frank Eitner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 10.121

8.  Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kandai Nozu; Kazumoto Iijima; Yuko Shima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2014-12-10       Impact factor: 3.714

9.  A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.

Authors:  Mark Haas; Jacobien C Verhave; Zhi-Hong Liu; Charles E Alpers; Jonathan Barratt; Jan U Becker; Daniel Cattran; H Terence Cook; Rosanna Coppo; John Feehally; Antonello Pani; Agnieszka Perkowska-Ptasinska; Ian S D Roberts; Maria Fernanda Soares; Hernan Trimarchi; Suxia Wang; Yukio Yuzawa; Hong Zhang; Stéphan Troyanov; Ritsuko Katafuchi
Journal:  J Am Soc Nephrol       Date:  2016-09-09       Impact factor: 10.121

10.  Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low-dose prednisone.

Authors:  Haiying Song; Haofei Hu; Fei Tang; Changchun Cao; Qijun Wan; Yongcheng He
Journal:  Exp Ther Med       Date:  2020-03-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.